NNK1 Antibody

What is NK1.1 and which mouse strains express this marker?

NK1.1 (also known as NKR-P1C, Ly-55, CD161b, and CD161c) is a surface marker predominantly expressed on natural killer (NK) cells and NKT cells in specific mouse strains. The expression of NK1.1 is strain-dependent, with positive expression in C57BL, FVB/N, and NZB mouse strains. Importantly, other common laboratory mouse strains including A, AKR, BALB/c, CBA/J, C3H, C57BR, C58, DBA/1, DBA/2, SJL, and 129 do not express NK1.1 or express variants not recognized by standard anti-NK1.1 antibodies . Some reports suggest that the PK136 monoclonal antibody binds to NKR-P1B on SJL/K NK cells, indicating cross-reactivity with related receptors in certain strains .

What are the primary applications of anti-NK1.1 antibodies in immunology research?

Anti-NK1.1 antibodies serve multiple critical functions in immunological research:

• Cell identification and phenotyping: Used in flow cytometry to identify NK cells and NKT cells in appropriate mouse strains

• In vivo depletion: PK136 clone is widely employed for NK cell depletion in experimental models

• Functional studies: Used to investigate NK cell roles in infection, malignancy, and inflammatory conditions

• Immunohistochemistry: Applied to tissue sections to identify and localize NK cells

• Blocking studies: Used to inhibit NK cell function in experimental settings

The versatility of anti-NK1.1 antibodies makes them indispensable tools for investigating innate immune responses in experimental systems.

How should researchers optimize NK cell depletion protocols using anti-NK1.1 antibodies?

Effective NK cell depletion requires careful protocol optimization:

• Dosing regimen: A typical protocol involves intraperitoneal (i.p.) injection of 200 μg mouse anti-NK1.1 antibodies (PK136 clone) at multiple timepoints. In the MA-ARDS model, successful depletion was achieved with injections at -2, 1, 4, and 7 days post-infection .

• Validation of depletion efficiency: Always confirm depletion efficiency by flow cytometry. In the referenced study, anti-NK1.1 treatment resulted in an 87% decrease in CD3−DX5+ cells, confirming substantial NK cell depletion .

• Alternative markers: Because of potential cross-reactivity issues, validate depletion using multiple NK cell markers (e.g., NK1.1, DX5, NKp46) to ensure specificity and completeness of depletion .

• Strain selection: Only use anti-NK1.1 for depletion in appropriate strains (C57BL, FVB/N, NZB). For other strains, alternative depletion strategies must be employed .

• Timing considerations: The effectiveness of depletion may vary based on timing. The referenced study showed that late depletion (injection at 6 days post-infection) resulted in >90% depletion of cNK cells .

For optimal results, researchers should pilot their depletion protocol and confirm efficiency before proceeding with full experiments.

What flow cytometry controls are essential when using anti-NK1.1 antibodies?

Rigorous flow cytometry controls are critical when using anti-NK1.1 antibodies to avoid misinterpretation:

• Fluorescence Minus One (FMO) controls: Essential for proper gating, especially when identifying potentially novel NK1.1+ populations. The referenced study used FMO controls to demonstrate that an unknown population was genuinely NK1.1+ but CD3− .

• Isotype controls: Use appropriate isotype controls (mouse IgG2a for PK136 clone) to account for non-specific binding .

• Fc receptor blocking: Pre-incubate samples with Fc receptor blocking reagents to minimize non-specific binding, though this may not eliminate all aspecific binding as demonstrated in the MA-ARDS model .

• Multiple NK markers: Include additional NK cell markers (DX5, NKp46) to confirm identity of NK cells and avoid misidentification of cells that bind anti-NK1.1 non-specifically .

• Strain controls: Include negative control strains (e.g., BALB/c) when first establishing protocols to confirm antibody specificity .

These controls are particularly important given the documented issues with non-specific binding of anti-NK1.1 antibodies to myeloid cells in certain disease models .

How can researchers address the issue of non-specific binding of anti-NK1.1 antibodies to myeloid cells?

Recent research has identified significant challenges with anti-NK1.1 antibody specificity. A 2024 study demonstrated that in a malaria infection model, anti-NK1.1 antibodies bound non-specifically to a population of myeloid cells, primarily monocytes and macrophages . To address this issue:

These findings highlight the importance of rigorous validation in disease models, as standard approaches established using healthy animals may not translate directly to pathological states.

What are the technical differences between using NK1.1 antibodies for in vitro studies versus in vivo depletion?

The applications of NK1.1 antibodies differ significantly between in vitro and in vivo contexts:

In vitro applications:

• Antibody formulation: For flow cytometry and immunohistochemistry, fluorochrome-conjugated antibodies (e.g., PE-conjugated) are typically used, with specific buffer formulations optimized for these applications .

• Concentration: Lower concentrations are generally used for staining protocols, with titration recommended to determine optimal signal-to-noise ratio .

• Clone considerations: While PK136 is the standard clone, its performance may vary between applications. Flow cytometry may require different optimization than immunohistochemistry .

• Storage and handling: PE-conjugated antibodies are particularly sensitive to freezing and should be stored at 4°C with minimal exposure to light .

In vivo depletion:

• Endotoxin levels: For in vivo applications, low-endotoxin preparations (<1.0 EU/mg) are essential to avoid non-specific immune activation .

• Formulation: Typically provided in phosphate-buffered saline without preservatives that could cause adverse reactions in vivo .

• Dosing regimen: Higher doses (typically 200 μg per injection) administered at specific intervals as demonstrated in the MA-ARDS model .

• Validation requirements: Functional effects must be validated through assessment of target cell depletion and monitoring for off-target effects .

Despite the documented non-specific binding in flow cytometry, in vivo depletion with anti-NK1.1 has been shown to be specific for cNK cells in the MA-ARDS model, suggesting differences in binding properties between these applications .

What is the role of NK cells in malaria-associated acute respiratory distress syndrome (MA-ARDS) based on anti-NK1.1 depletion studies?

Recent research utilizing anti-NK1.1 antibody depletion has provided important insights into the role of conventional NK (cNK) cells in MA-ARDS:

These findings contrast with previous conflicting reports on NK cell roles in malaria, highlighting the importance of model-specific investigations. The study also underscores the need for careful interpretation of NK cell studies in infectious disease models, particularly given the potential for non-specific antibody binding to activated myeloid cells that may be misidentified as NK cells .

How can researchers differentiate between conventional NK cells and other NK1.1-binding populations in disease models?

Distinguishing true NK cells from other populations that may bind NK1.1 antibodies requires a multi-faceted approach:

• Comprehensive marker panels: Use combinations of markers including:

  • NK1.1 (traditional NK marker)

  • DX5 (CD49b, alternative NK marker)

  • NKp46 (more specific NK receptor)

  • CD3 (to exclude NKT cells)

  • Myeloid markers (CD11b, F4/80, Ly6C) to identify potential non-specific binding populations

• Functional assays: Assess functional characteristics typical of NK cells:

  • Cytotoxicity against YAC-1 targets

  • IFN-γ production upon stimulation

  • Granzyme and perforin expression

• Careful gating strategy: Implement a gating strategy that accounts for potential non-specific binding:

  • Begin with stringent live/dead discrimination

  • Exclude doublets

  • Gate on lymphocyte morphology

  • Use CD3 to distinguish NK from NKT cells

  • Confirm NK identity with multiple markers (NK1.1+DX5+NKp46+)

• Parallel approaches: When possible, validate findings using genetic models (e.g., NKp46-DTR mice for NK cell depletion) in addition to antibody-based approaches .

In the MA-ARDS model, researchers identified an unknown NK1.1+ population that was CD3− but lacked other NK cell markers. Further characterization revealed these were actually monocytes and macrophages binding anti-NK1.1 non-specifically, likely via upregulated FcγR4 receptors during infection .

What is the historical significance of HNK-1 antibody in NK cell and neural research?

The HNK-1 antibody has a significant historical role bridging neuroscience and immunology:

• Dual specificity discovery: HNK-1 was initially developed as a marker for human NK cells but was subsequently found to strongly react with human peripheral nerve gangliosides in enzyme-linked immunosorbent assays .

• Cross-reactivity characterization: Detailed analysis showed that HNK-1 reacts with a minor ganglioside that chromatographs between GM1 and GD1a in peripheral nerves, demonstrating an unexpected cross-reactivity between neural and immune system antigens .

• Biochemical properties: The neural antigen recognized by HNK-1 was found to be insensitive to neuraminidase and pronase digestion, providing early insights into the biochemical nature of this epitope .

• Epitope identification: Later research identified the HNK-1 epitope as a unique carbohydrate structure (3-sulfated glucuronic acid) present on both neural cell adhesion molecules and certain glycolipids in the nervous system, as well as on subsets of NK cells .

This unexpected cross-reactivity between immune and neural antigens revealed by HNK-1 antibody led to important discoveries about shared glycobiology between these systems and highlights the value of thoroughly characterizing antibody specificities across different tissues and cell types.

How should researchers prepare tissue samples for optimal NK1.1 immunohistochemistry results?

For optimal immunohistochemical detection of NK1.1+ cells in tissue sections:

• Fixation protocol: Paraformaldehyde fixation has been demonstrated to preserve NK1.1 antigenicity. The referenced study successfully used paraformaldehyde-fixed, paraffin-embedded mouse spleen sections .

• Antibody dilution: Titrate the antibody concentration; a 1:100 dilution of purified anti-mouse NK1.1 (such as product MBS520387) has been reported as effective .

• Detection system: A DAB (3,3'-diaminobenzidine) detection system with a short (1 minute) development time provided optimal visualization in the referenced protocol .

• Antigen retrieval: While not explicitly mentioned in the search results, heat-induced epitope retrieval in citrate buffer (pH 6.0) is typically beneficial for formalin-fixed tissues.

• Controls: Include tissue sections from NK1.1-negative mouse strains (e.g., BALB/c) as negative controls, and spleen or lymph node sections from C57BL/6 mice as positive controls .

• Counter-staining: Light hematoxylin counterstaining allows visualization of tissue architecture while maintaining clear identification of DAB-positive NK cells.

This approach enables effective visualization of NK cells in tissue contexts, allowing for studies of NK cell distribution and tissue-specific responses in experimental models.

What alternative approaches can researchers use to study NK cells when anti-NK1.1 antibodies show non-specific binding?

Given the documented issues with non-specific binding of anti-NK1.1 antibodies, researchers should consider these alternatives:

• Alternative NK cell markers:

  • Anti-DX5 (CD49b) antibodies have shown greater specificity for NK cells in infection models

  • Anti-NKp46 antibodies provided specific staining of cNK cells even in models where NK1.1 showed non-specific binding

• Genetic approaches:

  • NKp46-DTR or NKp46-Cre mouse models allow for genetic targeting of NK cells

  • These approaches avoid the potential pitfalls of antibody-based identification or depletion

• Multi-parameter flow cytometry:

  • Define NK cells using combinations of markers (CD3−CD49b+NKp46+)

  • Include myeloid markers (CD11b, F4/80, Ly6C) to exclude potential non-specifically binding populations

• Functional identification:

  • Sort potential NK populations and validate through functional assays

  • Assess cytotoxicity, cytokine production, and transcriptional profiles

• Single-cell approaches:

  • Single-cell RNA sequencing can identify NK cells based on transcriptional profiles

  • This approach is independent of surface marker expression

These alternatives are particularly important in inflammatory or infectious disease models where changes in Fc receptor expression may affect antibody binding patterns .

What are the latest findings regarding aspecific binding mechanisms of anti-NK1.1 antibodies?

Recent research has provided important insights into the mechanisms of non-specific binding of anti-NK1.1 antibodies:

• Cell types affected: In a malaria infection model, an unknown population of cells binding anti-NK1.1 was identified as a mixture of myeloid cells, primarily monocytes and macrophages .

• Fcγ receptor involvement: The aspecific binding likely occurs via Fcγ receptors, particularly FcγR4, which was found to be upregulated on these myeloid cells during infection .

• Differential binding in applications: Interestingly, while flow cytometry staining showed significant non-specific binding, in vivo depletion using the same anti-NK1.1 clone remained specific for cNK cells .

• Resistance to standard blocking: This aspecific binding occurred despite the use of commercially available Fc blocking reagents, suggesting that standard blocking protocols may be insufficient in certain disease contexts .

• Infection-induced phenomenon: The aspecific binding was observed specifically in the context of Plasmodium berghei infection, suggesting that inflammatory or infection-related signals drive changes in Fc receptor expression that promote non-specific binding .

These findings highlight the importance of rigorous validation when using anti-NK1.1 antibodies in disease models and suggest that researchers should consider alternative approaches when studying NK cells in inflammatory contexts.